Development of a New Monoclonal Antibody for Breast Cancer Detection
Author Information
Author(s): M.R. Price, J.A. Pugh, F. Hudecz, W. Griffiths, E. Jacobs, I.M. Symonds, A.J. Clarke, W.C. Chan, R.W. Baldwin
Primary Institution: Cancer Research Campaign Laboratories and Department of Pharmaceutical Sciences, University of Nottingham
Hypothesis
Can a second generation IgG monoclonal antibody be developed against urinary mucins that are similar to those found in breast carcinomas?
Conclusion
The new antibody C595 shows similar reactivity to the original antibody NCRC-11 and may enhance breast cancer detection.
Supporting Evidence
- C595 and NCRC-11 antibodies showed virtually identical reactivity patterns with breast tumor tissues.
- C595 was developed from urinary mucins, which are abundant and similar to those found in breast carcinomas.
- Both antibodies reacted with epithelial mucins isolated from breast tumors and normal urine.
- Immunohistology revealed that C595 staining of normal tissues was similar to that of NCRC-11.
Takeaway
Scientists created a new antibody that can help find breast cancer by looking for special proteins in urine, similar to those found in breast tumors.
Methodology
Monoclonal antibodies were developed and tested using immunohistology and various assays to evaluate their reactivity with breast carcinoma tissues and urinary mucins.
Limitations
The study may not account for all variations in antibody reactivity across different tumor types.
Want to read the original?
Access the complete publication on the publisher's website